Pre-clinical evaluation of proteasome inhibitors for canine and human osteosarcoma

A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study

(2017) Danielle A. Jandial et al.   GYNECOLOGIC ONCOLOGY

PARP inhibitors: Clinical utility and possibilities of overcoming resistance

(2017) Benjamin G. Bitler et al.   GYNECOLOGIC ONCOLOGY

Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non–Germinal Center B-Cell–Like Diffuse Large B-Cell Lymphoma

(2017) John P. Leonard et al.   JOURNAL OF CLINICAL ONCOLOGY

Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes

(2017) O. Landgren et al.   JOURNAL OF INTERNAL MEDICINE

Apoptosis Induction and Gene Expression Profile Alterations of Cutaneous T-Cell Lymphoma Cells following Their Exposure to Bortezomib and Methotrexate

(2017) Vassiliki Mpakou et al.   PLoS One

The effects of proteasome inhibitors on bone remodeling in multiple myeloma

(2016) Maurizio Zangari et al.   BONE

Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma

(2016) Robert Z. Orlowski et al.   CANCER

A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors

(2016) Jeffrey R. Infante et al.   INVESTIGATIONAL NEW DRUGS

IAP antagonists sensitize murine osteosarcoma cells to killing by TNFα

(2016) Tanmay M. Shekhar et al.   Oncotarget

Bortezomib Inpatient Prescribing Practices in Free-Standing Children's Hospitals in the United States

(2016) Amanda M. DiNofia et al.   PLoS One

Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study

(2015) Peter M. Voorhees et al.   BRITISH JOURNAL OF HAEMATOLOGY

Effects of vascular endothelial growth factor expression on pathological characteristics and prognosis of osteosarcoma

(2015) Gang Han et al.   CLINICAL AND EXPERIMENTAL MEDICINE

Physiologically-based pharmacokinetic modeling of target-mediated drug disposition of bortezomib in mice

(2015) Li Zhang et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

A Phase I/II Study of Bortezomib in Combination with Paclitaxel, Carboplatin, and Concurrent Thoracic Radiation Therapy for Non–Small-Cell Lung Cancer: North Central Cancer Treatment Group (NCCTG)-N0321

(2015) Yujie Zhao et al.   Journal of Thoracic Oncology

Identification of Synergistic, Clinically Achievable, Combination Therapies for Osteosarcoma

(2015) Diana Yu et al.   Scientific Reports

Improved Survival in Osteosarcoma Patients with Atypical Low Vascularization

(2014) Pierre Kunz et al.   ANNALS OF SURGICAL ONCOLOGY

Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients

(2014) P. G. Richardson et al.   BLOOD

Efficacy of therapy with bortezomib in solid tumors: a review based on 32 clinical trials

(2014) Zebo Huang et al.   Future Oncology

Canine Osteosarcoma: A Naturally Occurring Disease to Inform Pediatric Oncology

(2014) J. M. Fenger et al.   ILAR JOURNAL

Protective Role of Humanin on Bortezomib-Induced Bone Growth Impairment in Anticancer Treatment

(2014) Emma Eriksson et al.   JNCI-Journal of the National Cancer Institute

Comparison of Carboplatin and Doxorubicin-Based Chemotherapy Protocols in 470 Dogs after Amputation for Treatment of Appendicular Osteosarcoma

(2014) L.E. Selmic et al.   JOURNAL OF VETERINARY INTERNAL MEDICINE

What do we know about canine osteosarcoma treatment? – review

(2014) M. Szewczyk et al.   VETERINARY RESEARCH COMMUNICATIONS

The effects of bortezomib on bone disease in patients with multiple myeloma

(2013) Mohamad Mohty et al.   CANCER

Bortezomib induces apoptosis and autophagy in osteosarcoma cells through mitogen-activated protein kinase pathway in vitro

(2013) Zhiyuan Lou et al.   JOURNAL OF INTERNATIONAL MEDICAL RESEARCH

Bortezomib (PS-341) Treatment Decreases Inflammation and Partially Rescues the Expression of the Dystrophin-Glycoprotein Complex in GRMD Dogs

(2013) Karla P. C. Araujo et al.   PLoS One

Carboplatin versus alternating carboplatin and doxorubicin for the adjuvant treatment of canine appendicular osteosarcoma: a randomized, phase III trial

(2013) K. A. Skorupski et al.   Veterinary and Comparative Oncology

The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma

(2012) Grit Hutter et al.   ANNALS OF HEMATOLOGY

Proteasome Inhibitors: An Expanding Army Attacking a Unique Target

(2012) Alexei F. Kisselev et al.   CHEMISTRY & BIOLOGY

Pharmacokinetic, Pharmacodynamic and Covariate Analysis of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma

(2012) Philippe Moreau et al.   CLINICAL PHARMACOKINETICS

A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma

(2012) Elisa Gallerani et al.   EUROPEAN JOURNAL OF CANCER

Phase-I/II Study of Bortezomib in Combination with Carboplatin and Bevacizumab as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer

(2012) Bilal Piperdi et al.   Journal of Thoracic Oncology

Toxicity Profile of Small-Molecule IAP Antagonist GDC-0152 Is Linked to TNF-α Pharmacology

(2012) Rebecca I. Erickson et al.   TOXICOLOGICAL SCIENCES

Dogs Are More Sensitive to Antagonists of Inhibitor of Apoptosis Proteins Than Rats and Humans: A Translational Toxicokinetic/Toxicodynamic Analysis

(2012) Harvey Wong et al.   TOXICOLOGICAL SCIENCES

Molecular subtypes of osteosarcoma identified by reducing tumor heterogeneity through an interspecies comparative approach

(2011) Milcah C. Scott et al.   BONE

Rapid Reduction in Donor-Specific Anti-Human Leukocyte Antigen Antibodies and Reversal of Antibody-Mediated Rejection With Bortezomib in Pediatric Heart Transplant Patients

(2011) William Robert Morrow et al.   TRANSPLANTATION

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

Bortezomib Plus Gemcitabine/Carboplatin as First-Line Treatment of Advanced Non-small Cell Lung Cancer: A Phase II Southwest Oncology Group Study (S0339)

(2010) Angela M. Davies et al.   Journal of Thoracic Oncology

Pharmacokinetic Modeling of Doxorubicin Pharmacokinetics in Dogs Deficient in ABCB1 Drug Transporters

(2010) D.L. Gustafson et al.   JOURNAL OF VETERINARY INTERNAL MEDICINE

Proteasome Inhibitors Enhance Gene Delivery by AAV Virus Vectors Expressing Large Genomes in Hemophilia Mouse and Dog Models: A Strategy for Broad Clinical Application

(2010) Paul E Monahan et al.   MOLECULAR THERAPY

Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma

(2009) K. Dunleavy et al.   BLOOD

Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes

(2009) L Galluzzi et al.   CELL DEATH AND DIFFERENTIATION

Influence of genetic background on tumor karyotypes: Evidence for breed-associated cytogenetic aberrations in canine appendicular osteosarcoma

(2009) Rachael Thomas et al.   CHROMOSOME RESEARCH

Proteasome inhibition with bortezomib suppresses growth and induces apoptosis in osteosarcoma

(2009) Yuriy Shapovalov et al.   INTERNATIONAL JOURNAL OF CANCER

Nonclinical Safety Assessment of the Histone Deacetylase Inhibitor Vorinostat

(2009) Janet S. Kerr et al.   INTERNATIONAL JOURNAL OF TOXICOLOGY

Phase I trial of carboplatin/paclitaxel/bortezomib and concurrent radiotherapy followed by surgical resection in Stage III non-small cell lung cancer

(2009) Martin J. Edelman et al.   LUNG CANCER

The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models

(2009) M. J. Williamson et al.   MOLECULAR CANCER THERAPEUTICS

Proteasome inhibition 1 h following ischemia protects GRK2 and prevents malignant ventricular tachyarrhythmias and SCD in a model of myocardial infarction

(2008) Shijun Huang et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

(2008) C. Tse et al.   CANCER RESEARCH